Patents Examined by David J. Blanchard
  • Patent number: 11925722
    Abstract: The present invention relates to a composition of a calcium phosphate such as tetracalcium phosphate or ?-TCP and an additive compound selected from nucleic acid or nucleotides, phospho(enol)pyruvic acid and phosphocreatine. The composition may be used as a tissue adhesive.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 12, 2024
    Assignee: GPBIO LTD.
    Inventors: Philip Procter, Michael Pujari-Palmer, Gerard Insley, Håkan Engqvist
  • Patent number: 11911517
    Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 27, 2024
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Javier Zumeta Perez, Blanca Alvarez Maluenda, Maria Pilar Sanz Saiz, Maria Elena Iglesias Piñeiro, Anthony Bell, Reinhard Walter
  • Patent number: 11911391
    Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: February 27, 2024
    Assignee: CEVA SANTE ANIMALE
    Inventors: Anne-Claire Le Meur, Florence Guimberteau
  • Patent number: 11911737
    Abstract: Provided herein is a method of preparing a ceramic material, the method including: providing a ceramic gel including a plurality of metal salts and compressing the ceramic gel thereby inducing stress-induced mineralization of the ceramic gel and formation of the ceramic material, wherein the ceramic gel exists in isolated form.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: February 27, 2024
    Assignee: City University of Hong Kong
    Inventors: Jian Lu, Yang Yang Li, Guobin Zhang, Jing Zhong, Peng Du, Zhengtao Xu
  • Patent number: 11912646
    Abstract: Provided are aromatic oligoamide foldamers and self-assembled compositions of the same. The aromatic oligoamide foldamers and compositions can form tube-like structures that can form pores in membranes. The pores can be used to transport ions and molecules, such as, for example, cryoprotective agents or therapeutic agents, through the membrane. The tube-like structures exhibit desirable stability at low temperatures.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: February 27, 2024
    Assignee: The Research Foundation for The State University of New York
    Inventor: Bing Gong
  • Patent number: 11911301
    Abstract: A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: February 27, 2024
    Assignee: Micell Medtech Inc.
    Inventors: Charles Douglas Taylor, James B. McClain, Mike Cole, James P. DeYoung, Clint Smoke
  • Patent number: 11903946
    Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: February 20, 2024
    Assignee: CEVA SANTE ANIMALE
    Inventors: Anne-Claire Le Meur, Florence Guimberteau
  • Patent number: 11903947
    Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: February 20, 2024
    Assignee: CEVA SANTE ANIMALE
    Inventors: Anne-Claire Le Meur, Florence Guimberteau
  • Patent number: 11896702
    Abstract: Long-lasting fragrance compositions are provided for. The fragrance compositions can include at least one fragrance compound and a glycoside. The glycoside can be selected from a Steviol glycoside, a glucosylated Steviol glycoside, a derivative of a Steviol glycoside, a derivative of a glucosylated Steviol glycoside, or combinations thereof. Also provided for are products including a long-lasting fragrance composition as above. The products can include perfumes, body care products, cosmetics, cleaning and laundry products, and the like.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: February 13, 2024
    Assignee: Almendra PTE LTD.
    Inventor: Inder Singh
  • Patent number: 11896684
    Abstract: Disclosed are a cosmetic composition having increased skin contact and makeup persistence and a method of manufacturing the same. The method includes: forming a powder continuous phase by rapidly mixing a powder and a film-forming agent; and obtaining a cosmetic composition in which a surface of the powder is compounded with the film-forming agent by heating the powder continuous phase for a predetermined time. In an embodiment, the cosmetic composition is manufactured by the method. In an embodiment, the cosmetic composition includes 5 wt % to 30 wt % of a powder, 0.1 wt % to 10 wt % of a film-forming agent, 10 wt % to 30 wt % of a silicone oil, and 0.1 wt % to 10 wt % of a spherical powder.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: February 13, 2024
    Assignee: COSMECCA KOREA CO., LTD.
    Inventors: Hyun Dae Cho, Byoung Moon Kim, Yeen Ji Kim, Goo Ho Kwon, Jin Young Kim
  • Patent number: 11883513
    Abstract: Disclosed is a hair care composition comprising from about 0.04 wt % to about 2 wt % azelaic acid; from about 0.04 wt % to about 1 wt % oleic acid; wherein the ratio of oleic acid to azelaic acid is from about 1:1 to about 1:3.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: January 30, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Jennifer Mary Marsh, Timothy James Felts
  • Patent number: 11878038
    Abstract: An exosome-based skincare product containing exosomes excreted by lab cultured human umbilical mesenchymal stem cells within a solvent. Most frequently the solvent is a mixture of water and glycerin. Optional ingredients such as skin-conditioning agents, antioxidants, surfactants, buffering agents, viscosity decreasing agents, viscosity increasing agents, peptides, binders, and/or humectants may be included.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: January 23, 2024
    Assignee: Elevai Labs, Inc.
    Inventor: Jordan Robert Plews
  • Patent number: 11857543
    Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: January 2, 2024
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
  • Patent number: 11857604
    Abstract: The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: January 2, 2024
    Assignee: NH THERAGUIX
    Inventors: Olivier Tillement, François Lux, Fabien Rossetti, Vu-Long Tran, Clélia Mathieu, Myleva Dahan
  • Patent number: 11857564
    Abstract: Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 2, 2024
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Tamar Auerbach-Nevo, Tali Negreanu-Gilboa, Hadas Alperin, Israel Nur
  • Patent number: 11857592
    Abstract: This invention relates to a method of treating Attention-Deficit Hyperactivity Disorder by orally administering to a subject a composition containing a Radix Polygalae (Polygala tenuifolia Willd) extract (such as PDC-1421). A solid dosage form of the composition can be prepared into the gelatin capsule. The oral administration of the composition in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extract.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: January 2, 2024
    Assignee: BIOLITE, INC.
    Inventors: Chi-Hsin Richard King, Hsien-Ming Wu, Howard Doong, Tsung-Shann Jiang
  • Patent number: 11850333
    Abstract: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: December 26, 2023
    Assignee: Micell Medtech Inc.
    Inventors: James P. DeYoung, Charles Douglas Taylor, James B. McClain, Clint Smoke, Mike Cole
  • Patent number: 11833115
    Abstract: Mineral-based composition and methods of use thereof in preventing skin damages, such as in subjects exposed to radiation, are provided.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: December 5, 2023
    Assignee: ANJON BIOLOGICS, INC.
    Inventor: Raziel Ronen
  • Patent number: 11813361
    Abstract: The present invention relates to a modified release pharmaceutical formulation comprising one or more sustained release granules that may be prepared by over-mixing and hot melt granulation. The invention also relates to disintegrating monolithic modified release tablets comprising the sustained release granules as an internal phase and an immediate release formulation of a drug or drugs as an external phase. The drug release profile from either these granules or these tables may be adjusted by adjusting the percentages of the formulation's components. In one application, the disintegrating monolithic modified release tablets comprise amoxicillin and clavulanate and have a dissolution profile similar to brand and generic “Augmentin XR® Bilayered Extended Release Tablets (1000 mg/62.5 mg)”. The invention also relates to a method of preparing the foregoing sustained release granules.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: November 14, 2023
    Assignee: PHARMAQUEST INTERNATIONAL CENTER, LLP
    Inventor: Mohammad Amin Mohammad
  • Patent number: 11806424
    Abstract: The invention relates to a cosmetic composition, in particular in the form of a liquid cosmetic composition, comprising in a physiological medium (i) at least a plate type filler with refractive index>1.6 and having a particle size between 1 ?m and 20 ?m, preferably between 1 ?m and 15 ?m, (ii) at least a silicon elastomer, preferably a non-emulsifying silicon elastomer, and (iii) at least a filler having an oil absorption capacity greater than or equal to 1 ml/g. The composition is preferably used as a skin care or make-up base or primer intended to decrease the visibility of skin imperfections, in particular the pores and make the pore hiding effect long lasting.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: November 7, 2023
    Assignee: L'OREAL
    Inventors: Romain Tachon, Momoko Shimizu